ReviewJournal of addiction medicine
Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations.
Review in Journal of addiction medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 73 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial
Buprenorphine for Analgesia in Older Adults With Acute Fractures in the Emergency Department: a Randomized Controlled Study
Who cites it
73 citing papers in PubMed, 2 syntheses or guidelines pooled it, 160 citations in OpenAlex.
- Strategy for effective analgesia with intravenous buprenorphine in patients with acute postoperative pain.BMC anesthesiology · 2025Pooled it
- Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review.Pharmacotherapy · 2022Pooled it
- Extended-Release vs Sublingual Buprenorphine in Pregnancy Through 12 Months Post Partum: A Randomized Clinical Trial.JAMA internal medicine · 2026Trial
- Subcutaneous Buprenorphine Extended-Release Use Among Pregnant and Postpartum Women.Obstetrics and gynecology · 2020Trial
- A randomized controlled study to compare analgesic efficacy of sublingual buprenorphine and intravenous tramadol in patients undergoing mastectomy.Medical gas researchTrial
- Article
- Long-Acting Injectable Buprenorphine in Prison: Insights From a Short-Answer Survey of People in the Criminal Justice System Commencing Long-Acting Injectable Buprenorphine During a Non-Randomised Clinical Trial.Drug and alcohol review · 2026Article
- Tramadol in drug-facilitated sexual assault: global case prevalence, pharmacology, and drug interactions.Journal of analytical toxicology · 2026Review
- Can Buprenorphine Be Overdosed? The Ceiling Effect and Its Clinical Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Onset of Analgesia in Rats (Rattus norvegicus) for Three Buprenorphine Formulations.Journal of the American Association for Laboratory Animal Science : JAALAS · 2026Article
- Buprenorphine Oral Lyophilisate for Treatment of Opioid Use Disorder: Pharmacology and Clinical Efficacy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Evaluation of opioid requirements in mechanically ventilated patients taking buprenorphine/naloxone prior to admission.Journal of critical care · 2026Article
- Reconsidering the usefulness of using long-acting injectable buprenorphine as a tapering tool: a case report of delayed withdrawal months after last dose.Frontiers in psychiatry · 2026Article
- Role of Cytokines in Wound Healing Following Wound Catheter Analgesia in Rats.Veterinary sciences · 2025Article
- Buvidal/Brixadi - a long-acting injectable buprenorphine formulation for the treatment of opioid dependence.Pain management · 2025Review
- Pharmacokinetic Evaluation of Topical Long-Acting Buprenorphine in New Zealand White Rabbits (Oryctolagus cuniculus).Journal of the American Association for Laboratory Animal Science : JAALAS · 2025Article
- Assessing buprenorphine treatment utilization and SAMHSA DATA waiver provider distribution in 2021: a real-world analysis in California.Scientific reports · 2025Article
- Extended-release Injectable Buprenorphine Initiation in the Emergency Department.The western journal of emergency medicine · 2025Article
- Cancer pain: molecular mechanisms and management.Molecular biomedicine · 2025Review
- Memory function in patients with opioid dependence treated with buprenorphine and methadone in comparison with healthy persons.Scientific reports · 2025Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
: Buprenorphine is an effective treatment for opioid use disorder. As a high-affinity, partial agonist for the mu-opioid receptor, buprenorphine suppresses opioid withdrawal and craving, reduces illicit opioid use, and blocks exogenous opioid effects including respiratory depression. Other pharmacologic benefits of buprenorphine are its superior safety profile compared with full opioid agonists and its long half-life that allows daily or less-than-daily dosing. New and innovative buprenorphine formulations, with pharmacokinetic profiles that differ from the original tablet formulation, continue to be developed. These include higher bioavailability transmucosal tablets and films and also 6-month implantable and monthly injectable products. This growing array of available formulations allows more choices for patients and increased opportunity for clinicians to individualize treatment; thus, it is important for buprenorphine prescribers to understand these differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.